Granules India Ltd (GRANULES) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Granules India Ltd (Granules) is a pharmaceutical manufacturing company, which carries out the research, development and manufacture of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs) and finished dosages (FDs). The company manufactures Paracetomol, Ibuprofen, Metformin, Guaifenesin and Methocarbamol. It has premier facilities for the manufacture of APIs, PFIs and FDs. With offices in India, the US, the UK, China and Colombia, the company offers products and solutions to companies across the world. Granules also provides contract research and manufacturing services. Its key clients include leading generic and branded pharmaceutical companies. Granules is headquartered in Hyderabad, Telangana, India.

Granules India Ltd (GRANULES) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 4
List of Figures 4
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Granules India Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Granules India Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Granules India Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Granules India Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Granules Pharma Enters into Licensing Agreement with USpharma Windlas 11
Equity Offering 12
Granules India Raises USD77.3 Million in Qualified Institutions Placement of Equity Shares 12
Acquisition 13
Granules Pharma to Acquire 12.5% Stake in Uspharma 13
Granules India Acquires Auctus Pharma for USD19 Million 14
Granules India Ltd - Key Competitors 15
Granules India Ltd - Key Employees 16
Granules India Ltd - Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Joint Venture 17
Recent Developments 18
Financial Announcements 18
May 24, 2018: Granules Indias Total Income increases by 18% to INR 1,703 Cr 18
Feb 08, 2018: Granules Indias Revenue from operation increases by 14% to INR 411 Cr 19
Nov 09, 2017: Granules Indias Revenue from operation increases by 8% to INR 393 Cr 20
Aug 14, 2017: Granules India Reported Its First Quarter Financial Results 2017 21
May 11, 2017: Granules Indias Revenue increases 4% to Rs. 1,435 Cr.; Net Profit surges 34% to Rs. 165 Cr 22
Jan 28, 2017: Granules Indias Net Profit rises by 34% to Rs. 39 Cr 23
Legal and Regulatory 24
Mar 26, 2018: Granules Indias Gagillapur and Jeedimetla facilities complete US FDA inspection 24
Feb 28, 2018: Granules Indias Chantilly facility received EIR from USFDA 25
Oct 06, 2017: Receipt of establishment report by Granules OmniChem facility from US FDA 26
Feb 03, 2017: Granules Indias Gagillapur facility completed INFARMED reinspection 27
Jan 06, 2017: Granules Indias Gagillapur Facility Completed INFARMED Inspection 28
Other Significant Developments 29
Aug 16, 2017: Granules India Reports Establishment Inspection Report (EIR) From US FDA-Reg. 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List Of Tables


Granules India Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Granules India Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Granules India Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Granules India Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Granules India Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Granules Pharma Enters into Licensing Agreement with USpharma Windlas 11
Granules India Raises USD77.3 Million in Qualified Institutions Placement of Equity Shares 12
Granules Pharma to Acquire 12.5% Stake in Uspharma 13
Granules India Acquires Auctus Pharma for USD19 Million 14
Granules India Ltd, Key Competitors 15
Granules India Ltd, Key Employees 16
Granules India Ltd, Subsidiaries 17
Granules India Ltd, Joint Venture 17

List Of Figures


Granules India Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Granules India Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Granules India Ltd, Medical Devices Deals, 2012 to YTD 2018 9

Granules India Ltd (GRANULES) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Granules India Ltd (Granules) is a pharmaceutical manufacturing company, which carries out the research, development and manufacture of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs) and finished dosages (FDs).

USD 250 View Report

Granules India Limited Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Granules India Limited Company Profile is a detailed strategic and analytical report on Granules India Limited. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

Assam Company India Ltd (ASSAMCO) - Financial and Strategic SWOT Analysis Review

Assam Company India Ltd (ASSAMCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled

USD 125 View Report

Danlaw Technologies India Ltd (532329) - Financial and Strategic SWOT Analysis Review

Danlaw Technologies India Ltd (DTIL) is a technology company that offers engineering solutions. The company offers automotive, digital signal processing, information technology, and intelligent security solutions. Its automotive products comprise

USD 300 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available